1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Alteogen Eyes First-Mover Advantage For Eylea Biosimilar

Cites Benefit Of Formulation Patent As Aflibercept Rival Completes Phase I Trial

 
• By Dave Wallace

Korea’s Alteogen believes that formulation patents granted in the EU, US and Japan as well as a pending process patent may offer it a first-mover advantage on biosimilar aflibercept. The firm has just completed a Phase I trial for its proposed rival to Eylea.

Chess White First Move
Alteogen Aims For A First-Mover Advantage On Biosimilar Eylea • Source: Shutterstock

Formulation patents granted in the EU, US and Japan, along with a pending process patent, may offer Alteogen a “first-mover advantage” with its biosimilar rival to Eylea (aflibercept), the Korean biotech specialist believes.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products